The monetary market is a machine powered by shifting opinions, and when the Federal Reserve introduced its newest rate of interest lower, these opinions pushed capital into healthcare and monetary shares.
Hims & Hers Well being TodayHIMSHims & Hers Well being$57.94 +0.12 (+0.21%) As of 10:36 AM Japanese It is a honest market worth value supplied by Polygon.io. Study extra.52-Week Vary$16.05▼$72.98P/E Ratio72.41Price Goal$38.92
This sort of sector rotation alerts the place traders see resilience—and alternative.
One title that sits on the intersection of healthcare and tech is Hims & Hers Well being Inc. NYSE: HIMS.
It’s a polarizing inventory in 2025: some see it as overhyped on account of its publicity to GLP-1 weight reduction remedies, whereas others consider it’s simply getting began.Get Hims & Hers Well being alerts:Signal Up
With robust quarterly outcomes and bullish analyst protection, traders could wish to reassess the place HIMS stands—and the place it may be headed.
Progress That’s Arduous to Ignore
When the Well being Care Choose Sector SPDR Fund NYSEARCA: XLV rose practically 1% on the day of the Fed lower, it hinted at a flight to stability. That’s additionally when Hims & Hers began displaying its hand.
In its newest Q2 2025 earnings, the corporate reported $544.8 million in income, a 73% enhance in comparison with the earlier 12 months. Most significantly, internet subscribers hit 2.4 million, a 31% enhance from the earlier 12 months. For a subscription-based platform, that form of development is not simply interesting, it is essential.
Common income per person grew from $57 in 2024 to $74 in 2025, a 30% rise, indicating higher retention and deeper spending, which boosts income and valuation.
And premium it’s. Hims & Hers trades at a price-to-book (P/B) ratio of 25.9x, properly above the medical sector common of 13.6x. That form of valuation often holds up solely when the market thinks development is each actual and sustainable.
Canaccord’s $68 Goal Highlights Bullish Analyst Sentiment
Regardless of HIMS buying and selling under its 52-week excessive, Wall Road stays cut up. The consensus value goal is $38.92, which means about 33% draw back from current costs. That consensus probably displays a cautious view primarily based on inventory volatility fairly than fundamentals.
However not all analysts agree.

Given the corporate’s current 32.9% inventory surge, this goal doesn’t look far-fetched. The rally seems pushed by robust earnings and investor optimism about decrease rates of interest fueling future reinvestment and enlargement.
Hims & Hers Well being, Inc. (HIMS) Value Chart for Monday, September, 22, 2025
Positioning Earlier than the Market Catches On
If Ripps is correct, and if extra analysts comply with go well with, the present value might characterize a window of alternative. Hims & Hers is working in a market candy spot: recurring income, rising buyer base, rising per-user spend, and a platform mannequin that scales.
These bullish on the broader telehealth and digital care house also needs to take into account how HIMS stacks up towards its opponents.
Though the dangers, each regulatory and operational, are substantial, the corporate’s stable fundamentals and market momentum justify the valuation.
Hims & Hers Well being: Robust Q2 Outcomes Validate Progress Technique
Hims & Hers Well being is now not only a speculative play. With robust subscriber development, enhancing margins, and a enterprise mannequin designed for scale, it is beginning to earn its valuation premium.
In the event you’re ready for proof of idea, Q2 may need simply delivered it. And if analyst sentiment shifts consistent with Canaccord’s $68 name, this inventory could have extra room to run.Earlier than you take into account Hims & Hers Well being, you may wish to hear this.MarketBeat retains observe of Wall Road’s top-rated and finest performing analysis analysts and the shares they suggest to their shoppers each day. MarketBeat has recognized the 5 shares that high analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Hims & Hers Well being wasn’t on the record.Whereas Hims & Hers Well being at the moment has a Scale back ranking amongst analysts, top-rated analysts consider these 5 shares are higher buys.MarketBeat’s analysts have simply launched their high 5 quick performs for October 2025. Study which shares have probably the most quick curiosity and commerce them. Enter your electronic mail tackle to see which corporations made the record.Get This Free Report

Like this text? Share it with a colleague.
Hyperlink copied to clipboard.